KS
Therapeutic Areas
Krystal Biotech Pipeline
| Drug | Indication | Phase |
|---|---|---|
| VYJUVEK® (beremagene geperpavec) | Dystrophic Epidermolysis Bullosa (DEB) | Approved |
| KB407 | Cystic Fibrosis (CF) | Phase 1 |
| KB408 | Alpha-1 Antitrypsin Deficiency (AATD) | Preclinical |
| KB301 | Aesthetic Indications | Phase 1 |
| KB105 | TGM1-deficient Autosomal Recessive Congenital Ichthyosis (ARCI) | Preclinical |
| KB104 | Netherton Syndrome | Preclinical |